Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T15:47:45.977Z.
Calculation as of: 2026-10-06T15:47:45.977Z.
Quote observation: 2026-10-06T15:44:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 789431897149b7eb66dfe5c794b774a541b173055368acfdd0e045abcb2ddd87
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$265.01M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$265.39M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$258.22M
Price/OCF Ratio
43.20
TTM Avg
27.05
3Y Avg
50.78
5Y Avg
58.49
Market Cap
$268.17M
Price/OCF Ratio
N/A
TTM Avg
64.10
3Y Avg
34.63
5Y Avg
150.74
Market Cap
$268.17M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$271.27M
Price/OCF Ratio
N/A
TTM Avg
134.67
3Y Avg
134.67
5Y Avg
134.67
Market Cap
$254.41M
Price/OCF Ratio
N/A
TTM Avg
30.64
3Y Avg
30.64
5Y Avg
30.64
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Palisade Bio, Inc. (PALI) | $262.97M | N/A | N/A | N/A | N/A |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $265.01M | N/A | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $265.39M | N/A | N/A | N/A | N/A |
| Anika Therapeutics, Inc. (ANIK)vs › | $258.22M | 43.20 | 27.05 | 50.78 | 58.49 |
| AC Immune S.A. (ACIU)vs › | $257.49M | N/A | 5.20 | 5.41 | 5.41 |
| OraSure Technologies, Inc. (OSUR)vs › | $268.17M | N/A | 64.10 | 34.63 | 150.74 |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $268.17M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $271.27M | N/A | 134.67 | 134.67 | 134.67 |
| Century Therapeutics, Inc. (IPSC)vs › | $254.41M | N/A | 30.64 | 30.64 | 30.64 |
| Quantum-Si incorporated (QSI)vs › | $251.43M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
